Ilse S Daehn | Mount Sinai

About Me

Dr. Daehn research laboratory investigates the cell-type specific responses and signals of glomerular disease progression in CKD. With particular focus in examing the signaling crosstalk between podocytes, endocapillary cells and mesangial cells that lead to irreversible segmental sclerosis characteristic of glomerular disease progression. The research aims to identify novel glomerular lesion-specific therapeutic targets.

Dr. Daehn holds a degree in Biotechnology (Honors) from Flinders University of South Australia. She performed a research placement at the Fundacion Jimenez Diaz, Madrid before starting her Doctorate studies at Flinders University of SA, and was awarded her PhD in 2007. She was a postdoctoral fellow at Cancer Research UK, in London and came to NYC to pursue a second postdoctoral fellowship at Mount Sinai.

Dr. Daehn is a member of DBRC and OAEM Steering Committees and former Co-chair of the Postdoc Executive Committee at Mount Sinai. She sits on NYC Tech Connect’s Entrepreneurial Scientist Advisory Panel.

Please visit her lab website at http://labs.icahn.mssm.edu/daehnlab/.

Language

English

Position

ASSOCIATE PROFESSOR | Medicine, Nephrology

Research Topics

Cell Biology, Kidney, Mitochondria, Oxidative Stress

Multi-Disciplinary Training Areas

Disease Mechanisms and Therapeutics (DMT)

Education

Bachelors, Flinders University

PhD, Flinders University

Awards

2019

NIDDK Basic Science Research Award

NMRI 17th Annual Workshop, Bethesda, MD

2017

Early Career Investigator Award Keystone Symposia

"Mitochondria Communications," Taos, NM

2016

4D Award - Pilot Project Grant

National Center for Advancing Translational Science

2015

Young Investigator Grant

National Kidney Foundation

2015

Quod Erat Demonstrandum (QED) Special Recognition Award

Icahn School of Medicine at Mount Siani

Research

My research focuses on exploring the complexity of signaling crosstalk between cells in the kidney. Particularly, my work aims to examine molecular mechanisms in the glomerulus that result in kidney disease progression and diabetic nephropathy in order to identify novel glomerular lesion-specific therapeutic targets and biomarkers. I have so far taken innovative approaches to examine the development of glomerular disease and the outcomes from this work have provided a fundamental paradigm shift in our current understanding of chronic kidney disease development.